(Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N,N-dimethyl benzamide hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N,N-dimethyl benzamide hydrochloride
• 英文别名: (Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N,N-dimethylbenzamide hydrochloride；4-[(Z)-2-(aminomethyl)-3-fluoroprop-2-enoxy]-N,N-dimethylbenzamide;hydrochloride
• 化学式: C₁₃H₁₇FN₂O₂*ClH
• 分子量: 288.75
• InChiKey: POABDGGPWQHQAS-VEZAGKLZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.0
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  55.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (Z)-tert-butyl 2-((4-(dimethylcarbamoyl)phenoxy)-methyl)-3-fluoroallylcarbamate 在 三氟乙酸 、 盐酸 作用下， 以 二氯甲烷 、 乙醚 、 水 、 乙酸乙酯 为溶剂， 反应 0.5h， 以71%的产率得到(Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N,N-dimethyl benzamide hydrochloride
  参考文献：
  名称：

  [EN] SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF
  [FR] INHIBITEURS DE SSAO 3-HALOGÉNOALLYLAMINES SUBSTITUÉES ET LEURS UTILISATIONS

  摘要：

  本发明涉及取代3-卤丙烯胺衍生物的制备和药用，其作为具有式（I）中定义的SSAO/VAP-1抑制剂。该发明还涉及使用式（I）化合物或其药用盐或衍生物的方法，用于治疗各种适应症，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病诱导疾病和癌症。

  公开号：

  WO2013163675A1

文献信息

• SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF
  申请人：Pharmaxis Ltd.

  公开号：US20150158813A1

  公开（公告）日：2015-06-11

  The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.

  本文描述了替代的3-卤代烯丙胺衍生物的制备和制药用途，作为具有公式I结构的SSAO/VAP-1抑制剂。还描述了使用公式I化合物或其药学上可接受的盐或衍生物治疗各种疾病的方法，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病诱导的疾病和癌症。
• Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160244406A1

  公开（公告）日：2016-08-25

  The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

  本发明涉及制备和药物应用具有式I结构的取代3-卤代烯丙胺衍生物作为SSAO/VAP-1抑制剂。该式在说明书中定义。本发明还涉及使用式I化合物或其药学上可接受的盐或衍生物的方法，用于治疗各种疾病，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病引起的疾病和癌症。
• Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US09302986B2

  公开（公告）日：2016-04-05

  The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.

  本文描述了替代的3-卤代烯丙胺衍生物的制备和药物应用，其具有公式I的结构，可作为SSAO/VAP-1抑制剂。本文还描述了使用公式I化合物或其药学上可接受的盐或衍生物治疗各种疾病的方法，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病诱导的疾病和癌症。
• Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10160723B2

  公开（公告）日：2018-12-25

  The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

  本发明涉及具有如说明书中定义的式 I 结构的取代 3-卤代烯丙胺衍生物作为 SSAO/VAP-1 抑制剂的制备和药物用途： 本发明还涉及使用式 I 化合物或其药学上可接受的盐或衍生物治疗各种适应症的方法，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病引起的疾病和癌症。
• SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF
  申请人：PharmAxis Ltd

  公开号：EP2844637A1

  公开（公告）日：2015-03-11